12,145 followers
RT @FrontOncology: New research: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real…
RT @FrontOncology: New research: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real…
New research: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience: Background Furmonertinib is the standard treatment option in the… https://t.co/dauN2
The efficacy of #furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience https://t.co/WkWzN1bDzl